Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update:
03 Apr 2019
Note:
-
Adis is an information provider.
-
Final gross price and currency may vary according to local VAT and billing address.
-
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
-
A link to download a PDF version of the trial profile will be included in your email receipt.